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Acute inability to mobilise resulting from probable donepezil-induced myoclonus: a case report 
Abstract 
Donepezil is a commonly prescribed cholinesterase inhibitor in Alzheimer’s dementia. We present a 
case of probable donepezil-induced generalised myoclonus causing total inability to mobilise in a 93 
year old woman.   
Case report  
A 93 year old woman living independently and mobilising with a stick, presented to hospital via her 
GP ‘off legs’. She was unable to mobilise due to the onset of frequent uncontrollable jerking 
movements of her limbs which were of sudden onset. She had recently been diagnosed with 
Alzheimer’s disease and had a background of hypertension. There was no history suggestive of 
seizures. She was taking donepezil 10mg daily, sodium docusate and calcium supplements.   
Neurological examination was normal with the exception of prominent multifocal myoclonic jerks, 
non-synchronously affecting all four limbs at rest. Investigation revealed no evidence of systemic 
infection or biochemical abnormality.  CT head showed generalised cerebral atrophy and small vessel 
disease, but no acute pathology.  A collateral history revealed that donepezil 5mg had been 
commenced 6 weeks previously which had been increased to 10mg, 7 days prior to admission. 
In the absence of other causes of myoclonus a working diagnosis of donepezil-induced myoclonus was 
made.  Donepezil was discontinued and over the following 48 hours the myoclonus diminished and 
then resolved.   
Discussion 
Donepezil hydrochloride is an acetylcholinesterase inhibitor licensed in the UK for the management 
of mild to moderately severe Alzheimer’s disease. Whilst it is generally well tolerated, side effects are 
reported in approximately 5% of patients, with the most common being gastrointestinal upset [1]. 
Muscle spasms are less common, occurring in 0.1 to 1% of patients, but myoclonus is not listed as a 
recognised side effect [1].   
This is the first report of donepezil induced myoclonus at a therapeutic dose (10mg). Notably the 
myoclonus caused significant impairment to daily function and ability to walk. A literature search 
limited to English language and humans was performed with the search strategy (donepezil OR Aricept 
OR Cholinesterase Inhibitors/adverse effects) AND (myoclon*) on Medline and Embase on 15.02.18, 
yielding 24 articles. Previous cases have described myoclonus occurring with donepezil overdose [2] 
and in conjunction with memantine use [3,4]. Myoclonus was described in a patient on memantine 
and donepezil 5mg, which worsened upon treatment with trimethoprim [3]. Upon cessation of 
memantine, the myoclonus ceased. Another case describes the emergence of prominent myoclonic 
jerks when memantine was added to donepezil which subsequently resolved on discontinuation of 
memantine [4]. In addition, data from a French phamacovigilance database reported myoclonus 
potentially having resulted from the use of cholinesterase inhibitors [5]. However, in this aggregated 
data causality cannot be reliably established.     
Conclusion  
Myoclonus can be classified according to the aetiology, clinical presentation or physiological source.  
The most common drug causes of symptomatic myoclonus are opiates, antidepressants, antibiotics 
and antipsychotics.  This case illustrates the emergence of severe, disabling myoclonus occurring with 
up-titration of donepezil at therapeutic dose, which resolved on discontinuation of the drug, strongly 
suggesting a causal association.  The case highlights the importance of careful examination to elicit an 
unusual cause of acute inability to mobilise and the necessity for consideration of potential drug 
toxicity. We highlight the importance of a rare but disabling complication of cholinesterase treatment 
which has previously been reported only after overdose or in conjunction with memantine 
prescription.  
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